gland 

10651
CET6TOEFLIELTS
单词释义
n.
词根词缀记忆/谐音联想记忆 补充/纠错
巧记速记
谐音记忆
g … * → gland n.腺
谐音记忆
g … * → gland n.腺
谐音记忆
“哥… * → gland n.腺
谐音记忆
g … * → gland n.腺
词性拓展记忆 / 词形拓展记忆
原形:gland复数:glands
词组和短语补充/纠错
pituitary gland 垂体
thyroid gland 甲状腺
salivary gland 唾液腺
pineal gland 松果体
adrenal gland 肾上腺
tear gland 泪腺
endocrine gland 内分泌腺
digestive gland 消化腺
preen gland 前腺
单词例句
Lisa's mother has an underactive adrenal gland.
丽萨的母亲肾上腺机能不全。
Mary's glands are swollen.
玛丽的腺体肿胀。
The glands in his neck are a little bit swollen.
他颈部的腺体有点肿胀。
The thyroid gland is an important hormone-producing gland located in the neck.
甲状腺是一个重要的激素生成腺体,位于颈部。
The pancreas is both an exocrine and endocrine gland, playing a vital role in digestion and metabolism.
胰腺既是外分泌腺也是内分泌腺,对消化和新陈代谢起着至关重要的作用。
The adrenal gland secretes hormones such as adrenaline during times of stress.
肾上腺在应激状态下会分泌诸如肾上腺素等激素。
The pituitary gland, often called the master gland, regulates other endocrine glands in the body.
垂体腺常被称为“主腺”,负责调节体内其他内分泌腺。
Salivary glands produce saliva, which aids in the digestion of food.
涎腺分泌唾液,有助于食物的消化。
The prostate gland is part of the male reproductive system and produces a fluid that nourishes sperm.
前列腺是男性生殖系统的一部分,能产生滋养精子的液体。
The parotid gland, the largest of the salivary glands, is located in front of each ear.
腮腺是最大的涎腺,位于每只耳朵的前方。
The thymus gland plays a crucial role in the development of the immune system, particularly in childhood.
胸腺在免疫系统的发育中起着关键作用,尤其是在儿童时期。
The pineal gland, also known as the third eye, regulates sleep patterns and circadian rhythms.
松果体,也称为第三眼,调节睡眠模式和昼夜节律。
In women, the ovaries are not only reproductive organs but also endocrine glands producing estrogen and progesterone.
在女性中,卵巢不仅是生殖器官,还是产生雌激素和孕激素的内分泌腺。
"The company offers solutions to address needs from protection to treatment, including contact lens brand Acuvue, fully automated treatment for meibomian gland dysfunction, extended depth of focus intraocular lenses and personalized laser vision correction.
“该公司提供解决方案,以满足从保护到治疗的需求,包括隐形眼镜品牌Acuvue、睑板腺功能障碍的全自动治疗、增焦深度人工晶状体和个性化激光视力矫正。
Shanghai-based Fosun Pharmaceutical Group will downsize its planned acquisition stake in the Indian generic drugmaker Gland Pharma to 74 percent from the previously announced 86 percent, according to a Fosun Pharmaceutical announcement released on Monday.
The founding shareholders of Gland Pharma said they have proposed maintaining a higher stake in the company as its operations continue to perform well.
The revisions of the agreement will not impact Fosun Pharmaceutical's acquisition of a controlling interest in Gland Pharma, according to the founding shareholders.
According to the announcement, the stake of Gland Pharma held by KKR Floorline Investment and the company's founding shareholders that will be acquired by Fosun Pharmaceutical is adjusted from 69.971 percent to 57.891 percent.
KKR will no longer own shares in Gland Pharma once the transaction is completed.
Chen Qiyu, chairman of Fosun Pharmaceutical, said that the integrated resources of Chinese and Indian pharmaceutical companies, such as Fosun Pharmaceutical's acquisition of Gland Pharma, will help promote the internationalization of Chinese pharmaceutical companies in research and development and generic drug export.
Fosun filed to acquire 86 percent in Gland Pharma in late July last year, with the acquisition amount reaching up to $1.26 billion.
Headquartered in Hyderabad, India, Gland Pharma is a leading Indian pure-play generic injectable pharmaceutical products company founded 39 years ago.
Shanghai Fosun Pharmaceutical Group announced on Monday it will acquire an approximately 74 percent stake in the Indian generic drug maker Gland Pharma, down from the 86 percent stake announced last July.
Founder shareholders of Gland Pharma said they have proposed to maintain a higher stake in the company, as it continues to perform well.
Revisions of the agreement will not impact Fosun Pharmaceutical's acquisition of a controlling interest in Gland Pharma, according to the founder shareholders.
According to the announcement, the stake of Gland Pharma held by KKR Floorline Investment and the company's founder shareholders that will be acquired by Fosun Pharmaceutical has been adjusted from 69.971 percent to 57.891 percent.
Headquartered in Gland Hyderabad, India, Pharma is a leading Indian pure play generic injectable pharmaceutical products company founded 39 years ago.
[Photo/VCG]China's healthcare giant Shanghai Fosun Pharmaceutical (Group) Co Ltd announced Monday it will purchase an approximate 74 percent stake in Indian drug maker Gland Pharma for more than $1 billion.
The stake's size has been revised down in this new announcement, as the company made a deal to acquire an approximate 86.08 percent stake in Gland Pharma for no more than $1.26 billion last July.
Gland Pharma's founder shareholders wanted to maintain a higher stake in the company because of its good performance, Fosun Pharmaceutical said in its announcement.
Though it will still hold a controlling interest in Gland Pharma, Fosun said the new agreement will establish closer cooperation between the management teams of the two companies.
According to the announcement, the $1 billion deal also included a payment of no more than $25 million contingent on consideration for Gland Pharma's Enoxaparin sales in the US market.
Gland Pharma, as one of the world's largest providers of injectable generic medicines, is India's first injectable drugs manufacturer to be approved by the US FDA.
The resource grafting of Chinese and Indian pharmaceutical companies represented by Fosun Pharma and Gland Pharma will help promote the internationalization of Chinese pharmaceutical companies in R&D innovation and generic drug export," Chen Qiyu, co-president of Fosun Group and chairman of Fosun Pharmaceutical, said in the announcement.
For Gland Pharma, the partnership with Fosun Pharmaceutical will enable the company to contribute further to the Indian bio-tech market, accelerate its investment plans and create more jobs in India's pharmaceutical industry, the Indian drug maker said in the announcement.
In August, the company's previous takeover deal of Gland Pharma was blocked by the Cabinet Committee on Economic Affairs of India and its termination date was extended to Sept 26, even though it received approval from China's National Development and Reform Commission.
[Photo/VCG]The Cabinet Committee on Economic Affairs of India (CCEA) has decided to block Shanghai Fosun Pharmaceutical Group's 8.5 billion yuan ($1.3 billion) takeover of Indian drugmaker Gland Pharma, Bloomberg reported Monday.
Fosun Pharmaceutical said in a statement issued on the morning of Tuesday that Gland Pharma has not received notice on the result of its review of the acquisition from the CCEA, chaired by Indian Prime Minister Narendra Modi.
Last July, Fosun Pharmaceutical agreed to buy an 86 percent stake in Gland Pharma for $1.3 billion.
Gland Pharma, based in the southern Indian city of Hyderabad, is one of world's largest providers of injectable generic medicines.
In the paper, the China Maternal and Child Health Association and UFH jointly asked postpartum rehabilitation facilities to achieve a set of goals, such as ensuring a more than 50 percent exclusive breastfeeding rate each month, conducting depression screening tests for new mothers every month, and reducing the incidence rate of mastitis — inflammation of the mammary gland — among new mothers and umbilical cord infection in newborns to less than 5 percent per month.
未经许可,严禁转发。QQ交流群:688169419
0
近30天助记贡献排行榜
网友新增怎么记信息
最新查询次数奖励榜
0